Myotonic Dystrophy Type 1 Clinical Trial
— TOM-VR-DM1Official title:
Virtual Reality-training in Theory of Mind in the Childhood Form of Myotonic Dystrophy Type 1
Verified date | November 2023 |
Source | Institut de Myologie, France |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The ability of an individual to conceive some alternative representations and to behave in a flexible manner would emerge from preschool age and drastically improve between the ages of 3 and 5 (Doebel and Zelazo, 2013). They constitute, according to Diamond (2013), a prerequisite for the development of the Theory of Mind (ToM). Deficits in Executive Functions (EF) may therefore interfere with the child's ability to understand and adapt to social situations. Treatment failures are often observed when traditional cognitive tools are used. This would be linked to the divergence between non-immersive tests and situations encountered in everyday life (Damasio, 1994; Priore Castelnuovo and Liccione, 2002). For this reason, an increasing number of researchers are using virtual reality for the rehabilitation of executive functions and Theory of Mind in patients with neurodevelopmental pathology (Millen, Edlin-White and Cobb, 2010) or brain damage (Le Gall, Besnard, Louisy, Richard and Allain 2008). There is currently no systematic evaluation of ToM in children with the infantile form of DM1 even though these abilities are considered particularly vulnerable and have a decisive impact on the subsequent development of interpersonal relationships. This research will focus on studying the socio-emotional disorders associated with the infantile form of Myotonic Dystrophy type 1 (DM1). The axis that we propose to develop more specifically will be an interventional study with the aim of remediation with children from 5 to 16 years old suffering from the infantile form of DM1 via a training protocol in low-immersion Virtual Reality (VR) centered on emotional processing and theory of mind.
Status | Enrolling by invitation |
Enrollment | 95 |
Est. completion date | July 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Years to 16 Years |
Eligibility | Inclusion Criteria: - 6 years and < 16 years of age - Written informed consent - Affiliate or beneficiary of a social security scheme - Able to comply with all protocol requirements - Infantile form of DM1 with molecular confirmation. - Development without incident in the first year - Normal development in the pre and neonatal period - Native language French Exclusion Criteria: - Unable to participate in the study - Inability to comply with protocol requirements - Congenital form of DM1 - IQ<70 (Intellectual Disability) |
Country | Name | City | State |
---|---|---|---|
France | Institut de Psychologie | Boulogne-Billancourt |
Lead Sponsor | Collaborator |
---|---|
Institut de Myologie, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | NEPSY II | Emotion Recognition and Standardized ToM | Through study completion, an average of 5 weeks | |
Secondary | WISC-V | Wechsler Scale is the international benchmark for measuring children's intelligence | Through study completion, on average 5 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00082108 -
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
|
||
Completed |
NCT02308657 -
Multicenter Observational Study of Myotonic Dystrophy Type 1
|
N/A | |
Enrolling by invitation |
NCT06316778 -
Pelvic Floor Muscle Training for Women With Myotonic Dystrophy
|
N/A | |
Completed |
NCT02312011 -
A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
|
Phase 1/Phase 2 | |
Recruiting |
NCT02269865 -
Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy
|
N/A | |
Completed |
NCT00577577 -
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
|
Phase 2 | |
Completed |
NCT02831504 -
PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study)
|
||
Recruiting |
NCT06075693 -
Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
|
||
Completed |
NCT02118779 -
Observational Prolonged Trial in Myotonic Dystrophy Type 1
|
N/A |